APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Agents

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroprotective Agents Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchNeuroprotective Agents Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Agents Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuroprotective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Agents Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Agents Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Neuroprotective Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuroprotective Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroprotective Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroprotective Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroprotective Agents is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neuroprotective Agents include Allon Therapeutics, Ceregene, Genervon Biopharmaceuticals, Neuren Pharmaceuticals and NeuroVive Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuroprotective Agents, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroprotective Agents, also provides the sales of main regions and countries. Of the upcoming market potential for Neuroprotective Agents, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroprotective Agents sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroprotective Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neuroprotective Agents sales, projected growth trends, production technology, application and end-user industry.

Neuroprotective Agents Segment by Company

Allon Therapeutics

Ceregene

Genervon Biopharmaceuticals

Neuren Pharmaceuticals

NeuroVive Pharmaceutical

Neuroprotective Agents Segment by Type

Ophthalmic Diseases

Neurodegenerative Disorders

Cerebrovascular Diseases

Traumatic CNS Injuries

Neuroprotective Agents Segment by Application

Hospitals

Clinics

Others

Neuroprotective Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neuroprotective Agents in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neuroprotective Agents manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroprotective Agents sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroprotective Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ophthalmic Diseases Major Manufacturers Table 3. Neurodegenerative Disorders Major Manufacturers Table 4. Cerebrovascular Diseases Major Manufacturers Table 5. Traumatic CNS Injuries Major Manufacturers Table 6. Global Neuroprotective Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals Major Manufacturers Table 8. Clinics Major Manufacturers Table 9. Others Major Manufacturers Table 10. Neuroprotective Agents Industry Trends Table 11. Neuroprotective Agents Industry Drivers Table 12. Neuroprotective Agents Industry Opportunities and Challenges Table 13. Neuroprotective Agents Industry Restraints Table 14. Global Neuroprotective Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Neuroprotective Agents Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Neuroprotective Agents Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Neuroprotective Agents Revenue Market Share by Region (2021-2026) Table 18. Global Neuroprotective Agents Revenue Market Share by Region (2027-2032) Table 19. Global Neuroprotective Agents Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k tons) Table 20. Global Neuroprotective Agents Sales by Region (2021-2026) & (k tons) Table 21. Global Neuroprotective Agents Sales by Region (2027-2032) & (k tons) Table 22. Global Neuroprotective Agents Sales Market Share by Region (2021-2026) Table 23. Global Neuroprotective Agents Sales Market Share by Region (2027-2032) Table 24. Global Neuroprotective Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Neuroprotective Agents Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Neuroprotective Agents Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Neuroprotective Agents Sales Market Share by Manufacturers (2021-2026) Table 28. Global Neuroprotective Agents Sales Price (US$/ton) of Manufacturers (2021-2026) Table 29. Global Neuroprotective Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Neuroprotective Agents Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Neuroprotective Agents Manufacturers, Product Type & Application Table 32. Global Neuroprotective Agents Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Neuroprotective Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Neuroprotective Agents Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Neuroprotective Agents Revenue Market Share by Type (2021-2026) Table 39. Global Neuroprotective Agents Revenue Market Share by Type (2027-2032) Table 40. Global Neuroprotective Agents Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 41. Global Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 42. Global Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 43. Global Neuroprotective Agents Sales Market Share by Type (2021-2026) Table 44. Global Neuroprotective Agents Sales Market Share by Type (2027-2032) Table 45. Global Neuroprotective Agents Price by Type (2021-2026) & (US$/ton) Table 46. Global Neuroprotective Agents Price by Type (2027-2032) & (US$/ton) Table 47. Global Neuroprotective Agents Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Neuroprotective Agents Revenue Market Share by Application (2021-2026) Table 51. Global Neuroprotective Agents Revenue Market Share by Application (2027-2032) Table 52. Global Neuroprotective Agents Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 53. Global Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 54. Global Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 55. Global Neuroprotective Agents Sales Market Share by Application (2021-2026) Table 56. Global Neuroprotective Agents Sales Market Share by Application (2027-2032) Table 57. Global Neuroprotective Agents Price by Application (2021-2026) & (US$/ton) Table 58. Global Neuroprotective Agents Price by Application (2027-2032) & (US$/ton) Table 59. Allon Therapeutics Company Information Table 60. Allon Therapeutics Business Overview Table 61. Allon Therapeutics Neuroprotective Agents Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 62. Allon Therapeutics Neuroprotective Agents Product Portfolio Table 63. Allon Therapeutics Recent Development Table 64. Ceregene Company Information Table 65. Ceregene Business Overview Table 66. Ceregene Neuroprotective Agents Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Ceregene Neuroprotective Agents Product Portfolio Table 68. Ceregene Recent Development Table 69. Genervon Biopharmaceuticals Company Information Table 70. Genervon Biopharmaceuticals Business Overview Table 71. Genervon Biopharmaceuticals Neuroprotective Agents Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Genervon Biopharmaceuticals Neuroprotective Agents Product Portfolio Table 73. Genervon Biopharmaceuticals Recent Development Table 74. Neuren Pharmaceuticals Company Information Table 75. Neuren Pharmaceuticals Business Overview Table 76. Neuren Pharmaceuticals Neuroprotective Agents Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Neuren Pharmaceuticals Neuroprotective Agents Product Portfolio Table 78. Neuren Pharmaceuticals Recent Development Table 79. NeuroVive Pharmaceutical Company Information Table 80. NeuroVive Pharmaceutical Business Overview Table 81. NeuroVive Pharmaceutical Neuroprotective Agents Sales (k tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. NeuroVive Pharmaceutical Neuroprotective Agents Product Portfolio Table 83. NeuroVive Pharmaceutical Recent Development Table 84. North America Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 87. North America Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 88. North America Neuroprotective Agents Sales Price by Type (2021-2026) & (US$/ton) Table 89. North America Neuroprotective Agents Sales Price by Type (2027-2032) & (US$/ton) Table 90. North America Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 93. North America Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 94. North America Neuroprotective Agents Sales Price by Application (2021-2026) & (US$/ton) Table 95. North America Neuroprotective Agents Sales Price by Application (2027-2032) & (US$/ton) Table 96. North America Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Neuroprotective Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 98. North America Neuroprotective Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 99. North America Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 100. North America Neuroprotective Agents Sales by Country (2021-2026) & (k tons) Table 101. North America Neuroprotective Agents Sales by Country (2027-2032) & (k tons) Table 102. North America Neuroprotective Agents Sales Price by Country (2021-2026) & (US$/ton) Table 103. North America Neuroprotective Agents Sales Price by Country (2027-2032) & (US$/ton) Table 104. United States Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 105. Canada Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 106. Mexico Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 107. Europe Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 110. Europe Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 111. Europe Neuroprotective Agents Sales Price by Type (2021-2026) & (US$/ton) Table 112. Europe Neuroprotective Agents Sales Price by Type (2027-2032) & (US$/ton) Table 113. Europe Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 116. Europe Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 117. Europe Neuroprotective Agents Sales Price by Application (2021-2026) & (US$/ton) Table 118. Europe Neuroprotective Agents Sales Price by Application (2027-2032) & (US$/ton) Table 119. Europe Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Neuroprotective Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. Europe Neuroprotective Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. Europe Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 123. Europe Neuroprotective Agents Sales by Country (2021-2026) & (k tons) Table 124. Europe Neuroprotective Agents Sales by Country (2027-2032) & (k tons) Table 125. Europe Neuroprotective Agents Sales Price by Country (2021-2026) & (US$/ton) Table 126. Europe Neuroprotective Agents Sales Price by Country (2027-2032) & (US$/ton) Table 127. Germany Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 128. France Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 129. U.K. Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 130. Italy Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 131. Russia Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 132. Spain Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 133. Netherlands Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 134. Switzerland Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 135. Sweden Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 136. Poland Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 137. China Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 138. China Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 139. China Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 140. China Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 141. China Neuroprotective Agents Sales Price by Type (2021-2026) & (US$/ton) Table 142. China Neuroprotective Agents Sales Price by Type (2027-2032) & (US$/ton) Table 143. China Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 144. China Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 145. China Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 146. China Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 147. China Neuroprotective Agents Sales Price by Application (2021-2026) & (US$/ton) Table 148. China Neuroprotective Agents Sales Price by Application (2027-2032) & (US$/ton) Table 149. Asia Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 152. Asia Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 153. Asia Neuroprotective Agents Sales Price by Type (2021-2026) & (US$/ton) Table 154. Asia Neuroprotective Agents Sales Price by Type (2027-2032) & (US$/ton) Table 155. Asia Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 158. Asia Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 159. Asia Neuroprotective Agents Sales Price by Application (2021-2026) & (US$/ton) Table 160. Asia Neuroprotective Agents Sales Price by Application (2027-2032) & (US$/ton) Table 161. Asia Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Neuroprotective Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Asia Neuroprotective Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Asia Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 165. Asia Neuroprotective Agents Sales by Country (2021-2026) & (k tons) Table 166. Asia Neuroprotective Agents Sales by Country (2027-2032) & (k tons) Table 167. Asia Neuroprotective Agents Sales Price by Country (2021-2026) & (US$/ton) Table 168. Asia Neuroprotective Agents Sales Price by Country (2027-2032) & (US$/ton) Table 169. Japan Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 170. South Korea Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 171. India Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 172. Australia Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 173. Taiwan Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 174. Southeast Asia Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 175. SAMEA Neuroprotective Agents Revenue by Type (2021-2026) & (US$ Million) Table 176. SAMEA Neuroprotective Agents Revenue by Type (2027-2032) & (US$ Million) Table 177. SAMEA Neuroprotective Agents Sales by Type (2021-2026) & (k tons) Table 178. SAMEA Neuroprotective Agents Sales by Type (2027-2032) & (k tons) Table 179. SAMEA Neuroprotective Agents Sales Price by Type (2021-2026) & (US$/ton) Table 180. SAMEA Neuroprotective Agents Sales Price by Type (2027-2032) & (US$/ton) Table 181. SAMEA Neuroprotective Agents Revenue by Application (2021-2026) & (US$ Million) Table 182. SAMEA Neuroprotective Agents Revenue by Application (2027-2032) & (US$ Million) Table 183. SAMEA Neuroprotective Agents Sales by Application (2021-2026) & (k tons) Table 184. SAMEA Neuroprotective Agents Sales by Application (2027-2032) & (k tons) Table 185. SAMEA Neuroprotective Agents Sales Price by Application (2021-2026) & (US$/ton) Table 186. SAMEA Neuroprotective Agents Sales Price by Application (2027-2032) & (US$/ton) Table 187. SAMEA Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 188. SAMEA Neuroprotective Agents Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 189. SAMEA Neuroprotective Agents Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 190. SAMEA Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032) & (k tons) Table 191. SAMEA Neuroprotective Agents Sales by Country (2021-2026) & (k tons) Table 192. SAMEA Neuroprotective Agents Sales by Country (2027-2032) & (k tons) Table 193. SAMEA Neuroprotective Agents Sales Price by Country (2021-2026) & (US$/ton) Table 194. SAMEA Neuroprotective Agents Sales Price by Country (2027-2032) & (US$/ton) Table 195. Brazil Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 196. Argentina Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 197. Chile Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 198. Colombia Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 199. Peru Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 200. Saudi Arabia Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 201. Israel Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 202. UAE Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 203. Turkey Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 204. Iran Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 205. Egypt Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Table 206. Key Raw Materials Table 207. Raw Materials Key Suppliers Table 208. Neuroprotective Agents Distributors List Table 209. Neuroprotective Agents Customers List Table 210. Research Programs/Design for This Report Table 211. Authors List of This Report Table 212. Secondary Sources Table 213. Primary Sources List of Figures Figure 1. Neuroprotective Agents Image Figure 2. Global Neuroprotective Agents Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Agents Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ophthalmic Diseases Image Figure 5. Neurodegenerative Disorders Image Figure 6. Cerebrovascular Diseases Image Figure 7. Traumatic CNS Injuries Image Figure 8. Global Neuroprotective Agents Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neuroprotective Agents Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Others Image Figure 13. Global Neuroprotective Agents Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Neuroprotective Agents Revenue (2021-2032) & (US$ Million) Figure 15. Global Neuroprotective Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Neuroprotective Agents Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Neuroprotective Agents Revenue Market Share by Region (2021-2032) Figure 18. Global Neuroprotective Agents Sales (2021-2032) & (k tons) Figure 19. Global Neuroprotective Agents Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 20. Global Neuroprotective Agents Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Neuroprotective Agents Sales YoY (2021-2032) & (k tons) Figure 22. Europe Neuroprotective Agents Sales YoY (2021-2032) & (k tons) Figure 23. China Neuroprotective Agents Sales YoY (2021-2032) & (k tons) Figure 24. Asia (Excluding China) Neuroprotective Agents Sales YoY (2021-2032) & (k tons) Figure 25. South America, Middle East and Africa Neuroprotective Agents Sales YoY (2021-2032) & (k tons) Figure 26. Global Neuroprotective Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Neuroprotective Agents Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Neuroprotective Agents Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Neuroprotective Agents Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Neuroprotective Agents Revenue Market Share by Type (2021-2032) Figure 32. Global Neuroprotective Agents Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 33. Global Neuroprotective Agents Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Neuroprotective Agents Sales Market Share by Type (2021-2032) Figure 35. Global Neuroprotective Agents Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Neuroprotective Agents Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Neuroprotective Agents Revenue Market Share by Application (2021-2032) Figure 38. Global Neuroprotective Agents Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 39. Global Neuroprotective Agents Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Neuroprotective Agents Sales Market Share by Application (2021-2032) Figure 41. North America Neuroprotective Agents Revenue Share by Type (2021-2032) Figure 42. North America Neuroprotective Agents Sales Share by Type (2021-2032) Figure 43. North America Neuroprotective Agents Revenue Share by Application (2021-2032) Figure 44. North America Neuroprotective Agents Sales Share by Application (2021-2032) Figure 45. North America Neuroprotective Agents Revenue Share by Country (2021-2032) Figure 46. North America Neuroprotective Agents Sales Share by Country (2021-2032) Figure 47. Europe Neuroprotective Agents Revenue Share by Type (2021-2032) Figure 48. Europe Neuroprotective Agents Sales Share by Type (2021-2032) Figure 49. Europe Neuroprotective Agents Revenue Share by Application (2021-2032) Figure 50. Europe Neuroprotective Agents Sales Share by Application (2021-2032) Figure 51. Europe Neuroprotective Agents Revenue Share by Country (2021-2032) Figure 52. Europe Neuroprotective Agents Sales Share by Country (2021-2032) Figure 53. China Neuroprotective Agents Revenue Share by Type (2021-2032) Figure 54. China Neuroprotective Agents Sales Share by Type (2021-2032) Figure 55. China Neuroprotective Agents Revenue Share by Application (2021-2032) Figure 56. China Neuroprotective Agents Sales Share by Application (2021-2032) Figure 57. Asia Neuroprotective Agents Revenue Share by Type (2021-2032) Figure 58. Asia Neuroprotective Agents Sales Share by Type (2021-2032) Figure 59. Asia Neuroprotective Agents Revenue Share by Application (2021-2032) Figure 60. Asia Neuroprotective Agents Sales Share by Application (2021-2032) Figure 61. Asia Neuroprotective Agents Revenue Share by Country (2021-2032) Figure 62. Asia Neuroprotective Agents Sales Share by Country (2021-2032) Figure 63. SAMEA Neuroprotective Agents Revenue Share by Type (2021-2032) Figure 64. SAMEA Neuroprotective Agents Sales Share by Type (2021-2032) Figure 65. SAMEA Neuroprotective Agents Revenue Share by Application (2021-2032) Figure 66. SAMEA Neuroprotective Agents Sales Share by Application (2021-2032) Figure 67. SAMEA Neuroprotective Agents Revenue Share by Country (2021-2032) Figure 68. SAMEA Neuroprotective Agents Sales Share by Country (2021-2032) Figure 69. Neuroprotective Agents Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neuroprotective Agents Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Ophthalmic Diseases
  • Neurodegenerative Disorders
  • Cerebrovascular Diseases
  • Traumatic CNS Injuries
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Allon Therapeutics
  • Ceregene
  • Genervon Biopharmaceuticals
  • Neuren Pharmaceuticals
  • NeuroVive Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroprotective Agents Market by Type
  3. 1.2.1 Global Neuroprotective Agents Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ophthalmic Diseases
  5. 1.2.3 Neurodegenerative Disorders
  6. 1.2.4 Cerebrovascular Diseases
  7. 1.2.5 Traumatic CNS Injuries
  8. 1.3 Neuroprotective Agents Market by Application
  9. 1.3.1 Global Neuroprotective Agents Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals
  11. 1.3.3 Clinics
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Neuroprotective Agents Market Dynamics
  1. 2.1 Neuroprotective Agents Industry Trends
  2. 2.2 Neuroprotective Agents Industry Drivers
  3. 2.3 Neuroprotective Agents Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Agents Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neuroprotective Agents Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neuroprotective Agents Revenue by Region
  3. 3.2.1 Global Neuroprotective Agents Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroprotective Agents Revenue by Region (2021-2026)
  5. 3.2.3 Global Neuroprotective Agents Revenue by Region (2027-2032)
  6. 3.2.4 Global Neuroprotective Agents Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neuroprotective Agents Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neuroprotective Agents Sales by Region
  9. 3.4.1 Global Neuroprotective Agents Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neuroprotective Agents Sales by Region (2021-2026)
  11. 3.4.3 Global Neuroprotective Agents Sales by Region (2027-2032)
  12. 3.4.4 Global Neuroprotective Agents Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neuroprotective Agents Revenue by Manufacturers
  2. 4.1.1 Global Neuroprotective Agents Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neuroprotective Agents Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neuroprotective Agents Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroprotective Agents Sales by Manufacturers
  6. 4.2.1 Global Neuroprotective Agents Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neuroprotective Agents Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neuroprotective Agents Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neuroprotective Agents Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neuroprotective Agents Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neuroprotective Agents Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neuroprotective Agents Manufacturers, Product Type & Application
  13. 4.7 Global Neuroprotective Agents Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neuroprotective Agents Market CR5 and HHI
  16. 4.8.2 2025 Neuroprotective Agents Tier 1, Tier 2, and Tier 3
5 Neuroprotective Agents Market by Type
  1. 5.1 Global Neuroprotective Agents Revenue by Type
  2. 5.1.1 Global Neuroprotective Agents Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neuroprotective Agents Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neuroprotective Agents Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neuroprotective Agents Sales by Type
  6. 5.2.1 Global Neuroprotective Agents Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroprotective Agents Sales by Type (2021-2032) & (k tons)
  8. 5.2.3 Global Neuroprotective Agents Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neuroprotective Agents Price by Type
6 Neuroprotective Agents Market by Application
  1. 6.1 Global Neuroprotective Agents Revenue by Application
  2. 6.1.1 Global Neuroprotective Agents Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neuroprotective Agents Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neuroprotective Agents Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neuroprotective Agents Sales by Application
  6. 6.2.1 Global Neuroprotective Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neuroprotective Agents Sales by Application (2021-2032) & (k tons)
  8. 6.2.3 Global Neuroprotective Agents Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neuroprotective Agents Price by Application
7 Company Profiles
  1. 7.1 Allon Therapeutics
  2. 7.1.1 Allon Therapeutics Company Information
  3. 7.1.2 Allon Therapeutics Business Overview
  4. 7.1.3 Allon Therapeutics Neuroprotective Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allon Therapeutics Neuroprotective Agents Product Portfolio
  6. 7.1.5 Allon Therapeutics Recent Developments
  7. 7.2 Ceregene
  8. 7.2.1 Ceregene Company Information
  9. 7.2.2 Ceregene Business Overview
  10. 7.2.3 Ceregene Neuroprotective Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Ceregene Neuroprotective Agents Product Portfolio
  12. 7.2.5 Ceregene Recent Developments
  13. 7.3 Genervon Biopharmaceuticals
  14. 7.3.1 Genervon Biopharmaceuticals Company Information
  15. 7.3.2 Genervon Biopharmaceuticals Business Overview
  16. 7.3.3 Genervon Biopharmaceuticals Neuroprotective Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Genervon Biopharmaceuticals Neuroprotective Agents Product Portfolio
  18. 7.3.5 Genervon Biopharmaceuticals Recent Developments
  19. 7.4 Neuren Pharmaceuticals
  20. 7.4.1 Neuren Pharmaceuticals Company Information
  21. 7.4.2 Neuren Pharmaceuticals Business Overview
  22. 7.4.3 Neuren Pharmaceuticals Neuroprotective Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Neuren Pharmaceuticals Neuroprotective Agents Product Portfolio
  24. 7.4.5 Neuren Pharmaceuticals Recent Developments
  25. 7.5 NeuroVive Pharmaceutical
  26. 7.5.1 NeuroVive Pharmaceutical Company Information
  27. 7.5.2 NeuroVive Pharmaceutical Business Overview
  28. 7.5.3 NeuroVive Pharmaceutical Neuroprotective Agents Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 NeuroVive Pharmaceutical Neuroprotective Agents Product Portfolio
  30. 7.5.5 NeuroVive Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Neuroprotective Agents Market Size by Type
  2. 8.1.1 North America Neuroprotective Agents Revenue by Type (2021-2032)
  3. 8.1.2 North America Neuroprotective Agents Sales by Type (2021-2032)
  4. 8.1.3 North America Neuroprotective Agents Price by Type (2021-2032)
  5. 8.2 North America Neuroprotective Agents Market Size by Application
  6. 8.2.1 North America Neuroprotective Agents Revenue by Application (2021-2032)
  7. 8.2.2 North America Neuroprotective Agents Sales by Application (2021-2032)
  8. 8.2.3 North America Neuroprotective Agents Price by Application (2021-2032)
  9. 8.3 North America Neuroprotective Agents Market Size by Country
  10. 8.3.1 North America Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neuroprotective Agents Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Neuroprotective Agents Market Size by Type
  2. 9.1.1 Europe Neuroprotective Agents Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neuroprotective Agents Sales by Type (2021-2032)
  4. 9.1.3 Europe Neuroprotective Agents Price by Type (2021-2032)
  5. 9.2 Europe Neuroprotective Agents Market Size by Application
  6. 9.2.1 Europe Neuroprotective Agents Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neuroprotective Agents Sales by Application (2021-2032)
  8. 9.2.3 Europe Neuroprotective Agents Price by Application (2021-2032)
  9. 9.3 Europe Neuroprotective Agents Market Size by Country
  10. 9.3.1 Europe Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neuroprotective Agents Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Neuroprotective Agents Market Size by Type
  2. 10.1.1 China Neuroprotective Agents Revenue by Type (2021-2032)
  3. 10.1.2 China Neuroprotective Agents Sales by Type (2021-2032)
  4. 10.1.3 China Neuroprotective Agents Price by Type (2021-2032)
  5. 10.2 China Neuroprotective Agents Market Size by Application
  6. 10.2.1 China Neuroprotective Agents Revenue by Application (2021-2032)
  7. 10.2.2 China Neuroprotective Agents Sales by Application (2021-2032)
  8. 10.2.3 China Neuroprotective Agents Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroprotective Agents Market Size by Type
  2. 11.1.1 Asia Neuroprotective Agents Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neuroprotective Agents Sales by Type (2021-2032)
  4. 11.1.3 Asia Neuroprotective Agents Price by Type (2021-2032)
  5. 11.2 Asia Neuroprotective Agents Market Size by Application
  6. 11.2.1 Asia Neuroprotective Agents Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neuroprotective Agents Sales by Application (2021-2032)
  8. 11.2.3 Asia Neuroprotective Agents Price by Application (2021-2032)
  9. 11.3 Asia Neuroprotective Agents Market Size by Country
  10. 11.3.1 Asia Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neuroprotective Agents Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroprotective Agents Market Size by Type
  2. 12.1.1 SAMEA Neuroprotective Agents Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neuroprotective Agents Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neuroprotective Agents Price by Type (2021-2032)
  5. 12.2 SAMEA Neuroprotective Agents Market Size by Application
  6. 12.2.1 SAMEA Neuroprotective Agents Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neuroprotective Agents Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neuroprotective Agents Price by Application (2021-2032)
  9. 12.3 SAMEA Neuroprotective Agents Market Size by Country
  10. 12.3.1 SAMEA Neuroprotective Agents Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neuroprotective Agents Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neuroprotective Agents Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neuroprotective Agents Value Chain Analysis
  2. 13.1.1 Neuroprotective Agents Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neuroprotective Agents Production Mode & Process
  6. 13.2 Neuroprotective Agents Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neuroprotective Agents Distributors
  9. 13.2.3 Neuroprotective Agents Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst